Primer: Broncus (2216 HK) - Aug 2026
Broncus is a pre-profitability medical device company at a critical commercialization juncture, focusing on innovative, minimally invasive...
98 Views
APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla
Hengrui got NMPA approval for long-acting insulin. FDA approves Otsuka’s new CNS drug. Pharmaessentia announced positive topline result from Phase...
136 Views
APAC Healthcare Weekly (January 18) – ImmuneOnco, Wuxi Bio, Eisai, Daiichi, SK Biopharm, HK Inno.N
ImmuneOnco got trial approval for atherosclerosis drug candidate, timdarpacept in China. Eisai secures rights to NSCLC drug taletrectinib. HK inno...
411 Views
“Sudden Death” of Silicon Valley Bank (SVB) - The Impact on China Healthcare
SVB's "sudden death" would affect Chinese healthcare companies. Investors need to reassess the risks of related companies.We don't think SVB’s woes...
716 Views
HSBC (5 HK)'s Clean Offer for Hang Seng (11 HK)'s Minorities
Assuming five months to wrap this, pay up to HK$148/share for a 15% annualised return. Including the third interim dividend of HK$1.20/share.
1.1k Views